{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:23:31Z","timestamp":1781706211776,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515110963"],"award-info":[{"award-number":["2021A1515110963"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.bbrc.2023.149314","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T07:14:37Z","timestamp":1700810077000},"page":"149314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Pemigatinib, a selective FGFR inhibitor overcomes ABCB1-mediated multidrug resistance in cancer cells"],"prefix":"10.1016","volume":"691","author":[{"given":"Chao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-na","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-qi","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zun-Jie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3054-5397","authenticated-orcid":false,"given":"Jian-ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2023.149314_bib1","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s00018-008-8111-5","article-title":"An overview of cancer multidrug resistance: a still unsolved problem","volume":"65","author":"Lage","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbrc.2023.149314_bib2","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2023.149314_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.canlet.2014.03.013","article-title":"Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches","volume":"347","author":"Wu","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2023.149314_bib4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fgene.2015.00157","article-title":"DNA repair mechanisms in cancer development and therapy","volume":"6","author":"Torgovnick","year":"2015","journal-title":"Front. Genet."},{"key":"10.1016\/j.bbrc.2023.149314_bib5","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1021\/cr9000226","article-title":"ABC efflux pump-based resistance to chemotherapy drugs","volume":"109","author":"Eckford","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bbrc.2023.149314_bib6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","article-title":"In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor","volume":"41","author":"Reese","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbrc.2023.149314_bib7","doi-asserted-by":"crossref","first-page":"652","DOI":"10.2174\/156800909789056999","article-title":"Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents","volume":"9","author":"Rochat","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.bbrc.2023.149314_bib8","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1101\/gr.184901","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"11","author":"Dean","year":"2001","journal-title":"Genome Res."},{"key":"10.1016\/j.bbrc.2023.149314_bib9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3109\/10409238.2014.953626","article-title":"Diversity in ABC transporters: type I, II and III importers","volume":"49","author":"Rice","year":"2014","journal-title":"CRIT REV BIOCHEM MOL"},{"key":"10.1016\/j.bbrc.2023.149314_bib10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.canlet.2015.10.010","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade","volume":"370","author":"Chen","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2023.149314_bib11","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1042\/BST20150139","article-title":"ABC transporter research: going strong 40 years on","volume":"43","author":"Theodoulou","year":"2015","journal-title":"Biochem. Soc. T"},{"key":"10.1016\/j.bbrc.2023.149314_bib12","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1016\/j.biomaterials.2013.01.101","article-title":"Cellular uptake, intracellular trafficking, and antitumor efficacy of doxorubicin-loaded reduction-sensitive micelles","volume":"34","author":"Cui","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbrc.2023.149314_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fonc.2014.00041","article-title":"Complex interplay between the P-glycoprotein multidrug efflux pump and the membrane: its role in modulating protein function","volume":"4","author":"Sharom","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2023.149314_bib14","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.ajpath.2010.10.029","article-title":"Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model","volume":"178","author":"Bao","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbrc.2023.149314_bib15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drup.2016.05.001","article-title":"Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies","volume":"27","author":"Li","year":"2016","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.bbrc.2023.149314_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.canlet.2018.10.020","article-title":"Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: in vitro and in vivo","volume":"442","author":"De Vera","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2023.149314_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24234383","article-title":"Tetrandrine interaction with ABCB1 reverses multidrug resistance in cancer cells through competition with anti-cancer drugs followed by downregulation of ABCB1 expression","volume":"24","author":"Liao","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bbrc.2023.149314_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186856","article-title":"FGFR fusions in cancer: from diagnostic approaches to therapeutic intervention","volume":"21","author":"De Luca","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2023.149314_bib19","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1158\/1541-7786.MCR-10-0168","article-title":"Roles of fibroblast growth factor receptors in carcinogenesis","volume":"8","author":"Haugsten","year":"2010","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bbrc.2023.149314_bib20","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"Powering precision medicine through an international consortium","volume":"7","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbrc.2023.149314_bib21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cytogfr.2015.03.003","article-title":"Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations","volume":"26","author":"Gallo","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bbrc.2023.149314_bib22","article-title":"INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2023.149314_bib23","doi-asserted-by":"crossref","first-page":"10666","DOI":"10.1021\/acs.jmedchem.1c00713","article-title":"Discovery of pemigatinib: a potent and selective fibroblast growth factor receptor (FGFR) inhibitor","volume":"64","author":"Wu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2023.149314_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10030601","article-title":"Infigratinib (BGJ 398), a pan-FGFR inhibitor, targets P-glycoprotein and increases chemotherapeutic-induced mortality of multidrug-resistant tumor cells","volume":"10","author":"Boichuk","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbrc.2023.149314_bib25","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3389\/fonc.2020.00955","article-title":"Erdafitinib antagonizes ABCB1-mediated multidrug resistance in cancer cells","volume":"10","author":"Feng","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2023.149314_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00280-013-2184-z","article-title":"PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells","volume":"72","author":"Patel","year":"2013","journal-title":"Cancer Chemoth. Pharm."},{"key":"10.1016\/j.bbrc.2023.149314_bib27","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3389\/fcell.2020.00865","article-title":"Bruton's tyrosine kinase (BTK) inhibitor RN486 overcomes ABCB1-mediated multidrug resistance in cancer cells","volume":"8","author":"Dong","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbrc.2023.149314_bib28","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3389\/fonc.2020.01219","article-title":"NVP-CGM097, an HDM2 inhibitor, antagonizes ATP-binding cassette subfamily B member 1-mediated drug resistance","volume":"10","author":"Zhang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2023.149314_bib29","article-title":"Overexpression of ABCB1 associated with the resistance to the KRAS-G12C specific inhibitor ARS-1620 in cancer cells","volume":"13","author":"Dong","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2023.149314_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254205","article-title":"Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer","volume":"16","author":"McCorkle","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2023.149314_bib31","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.canlet.2018.10.007","article-title":"Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells","volume":"440\u2013441","author":"Ji","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2023.149314_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2023.149314_bib33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejmech.2017.07.062","article-title":"Overcoming ABC transporter-mediated multidrug resistance: the dual role of tyrosine kinase inhibitors as multitargeting agents","volume":"142","author":"Beretta","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"Pt 2","key":"10.1016\/j.bbrc.2023.149314_bib34","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1042\/bj3080381","article-title":"Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells","volume":"308","author":"Sharom","year":"1995","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbrc.2023.149314_bib35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-022-01512-0","article-title":"PBK\/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study","volume":"21","author":"Yang","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbrc.2023.149314_bib36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bcp.2018.10.028","article-title":"Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance","volume":"158","author":"Ji","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2023.149314_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010238","article-title":"The selective class IIa histone deacetylase inhibitor TMP195 resensitizes ABCB1- and ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs","volume":"21","author":"Wu","year":"2019","journal-title":"Int. J. Mol. Sci."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X23014080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X23014080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:07:59Z","timestamp":1777399679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X23014080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":37,"alternative-id":["S0006291X23014080"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2023.149314","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pemigatinib, a selective FGFR inhibitor overcomes ABCB1-mediated multidrug resistance in cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2023.149314","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"149314"}}